Business Wire17h
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata
Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating ...
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ('BioRay') announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed C ...
PharmiWeb22h
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
PipelineReview.com4h
Rondo Therapeutics Presents Preclinical Data at ASCO GU for its Novel CD28 x Nectin-4 Costimulatory Bispecific Antibody for Advanced Bladder Cancer
Company plans to initiate a Phase 1/b trial in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end ...
Inflammation-triggering cellular pathway identified as potential new drug target for Alzheimer's disease
A team of researchers from the Keck School of Medicine of USC has unlocked the details of a cellular pathway that triggers ...
healthcare-in-europe.com23h
Replicating tumours to assess cancer immunotherapy efficacy
The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their ...